Alzheimer DiseasePhase 1TAURUS-1980NCT07158905
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
A Phase 1 study testing AV-1980R 20 µg, AV-1980R 60 µg and AV-1980R 180 µg in people with Alzheimer Disease and Preclinical Alzheimer's Disease, run by Institute for Molecular Medicine at 6 sites in United States.
Trial summary
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Read more about this study
- Who is it for?
- Ages 65 to 80 years
- Conditions the study is for
- Alzheimer Disease, Preclinical Alzheimer's Disease
- What is being tested?
- AV-1980R 20 µg, AV-1980R 60 µg and AV-1980R 180 µg
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 48 participants
- Where
- 6 sitesUnited States
- Study dates
- 23 Jun 2026to 15 Oct 2029
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 80 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Male or postmenopausal or surgically sterile female, 65 to 80 years of age, inclusive.
- Cognitively unimpaired participant with preclinical Alzheimer's disease who meets all of the following:
- Clinical Dementia Rating global score of 0 at Screening. Mini-Mental State Examination score ≥26, with education adjustment at Screening.
- Plasma p-tau217/Aβ42 ratio ≥0.00738 measured using Lumipulse (Fujirebio). A prior positive result obtained within 12 months before Screening may be accepted but must be confirmed by the central laboratory.
- Sight and hearing, including use of a hearing aid, sufficient to comply with study procedures.
- Stable concomitant medications. Participants receiving fluctuating medication or treatment may be considered if the underlying condition is controlled.
- Signed informed consent before any study-related procedure. Ability, in the Investigator's opinion, to understand the study and comply with protocol requirements.
Who cannot join
- Screening MRI showing any of the following:
- More than one noncortical lacunar infarct greater than 1.5 cm. Any territorial infarct greater than 1.5 cm. Combined microbleeds and areas of leptomeningeal hemosiderosis greater than 5, or disseminated leptomeningeal hemosiderosis.
- Any other significant cerebral abnormality, including ARIA-E. Contraindication to MRI, including non-MRI-safe implanted metallic devices or clinically significant claustrophobia.
- Serious illness requiring systemic treatment or hospitalization within 4 weeks before study entry.
- Clinically relevant cardiovascular, respiratory, gastrointestinal, endocrine, immunologic, hematologic, systemic disease, or major surgery that could interfere with participation or follow-up.
- Insulin-dependent diabetes. Clinically relevant cardiac arrhythmia, palpitation, conduction abnormality, prolonged QT interval, or bundle branch block.
Show all 14Show fewer
- Pre-existing autoimmune disease. C-SSRS score of 3 or higher. History of seizure disorder, except permitted stable use of certain antiepileptic medications for chronic pain.
- Any medical, psychological, or social condition that could interfere with participation, compliance, or participant safety.
- Participation in another investigational drug study or use of an investigational drug within 30 days or 5 half-lives, whichever is longer, before dosing.
- Prior tau or amyloid-beta immunotherapy within 1 year before Screening. Use of specified immunomodulatory or growth-stimulating treatments within 30 days before study entry.
- Chronic use for more than 3 months of warfarin, other coumarin derivatives, anticoagulants, or an antiplatelet agent such as clopidogrel.
- Parenteral immunoglobulin preparations, blood products, or plasma derivatives. History of severe local or systemic vaccination reactions or significant allergic reactions.
- Clinically significant laboratory abnormalities at Screening, including ALT or AST greater than 1.5 times the upper limit of normal.
- Positive testing for HIV-1 or HIV-2, hepatitis B surface antigen, or hepatitis C.
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
United States6 sites, 6 recruiting
- Recruiting
Comprehensive Center for Brain Health
Boca Raton, Florida, 33433
Shanell Disla, 561-869-6825, sxd1210@med.miami.edu
Alyssa Gosling, 561-869-6820, aeg364@med.miami.edu
- Recruiting
Alzheimer's Research and Treatment Center (Columbus)
Columbus, Georgia, 31904
Dawn Pitman, 776-653-8455, dpitman@researchalz.com
Kylie Gilbert, 706-653-8455, kgilbert@researchalz.com
- Recruiting
Palm Springs Community Health Center
Miami Lakes, Florida, 33014
Mailin Perez, 305-431-7493, mperez@palmspringschc.com
Vivianne Gonzalez, 786-334-6675, vgonzalez@palmspringschc.com
- Recruiting
Alzheimer's Research and Treatment Center (Stuart)
Stuart, Florida, 34996
Cristina Healy, 772-675-0000, cchirino@researchalz.com
Emma LaVopa, 772-675-0000, elavopa@researchalz.com
- Recruiting
University of South Florida
Tampa, Florida, 33613
Randa Abdulkarim, 656-244-6936, randaa@usf.edu
Genesis Estremera, 813-440-9452, gestremera@usf.edu
- Recruiting
Alzheimer's Research and Treatment Center (Wellington)
Wellington, Florida, 33414
Megan Moran, 561-209-2400, mmoran@researchalz.com
Jasmine Flores, 561-209-2400, jflores@researchalz.com
About this study
Official title: A Phase I, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of AV-1980R in Participants With Preclinical Alzheimer's Disease
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65 to 80 years with biomarker evidence of preclinical Alzheimer's disease will be enrolled into three ascending-dose cohorts.
Read the detailed description
This study will evaluate AV-1980R, a MultiTEP-based active immunotherapy formulated with Advax-CpG55.2 adjuvant, in participants with preclinical Alzheimer's disease. Up to 48 participants aged 65 to 80 years will be randomized in a 3:1 ratio to receive AV-1980R or placebo in three ascending-dose cohorts of 20 µg, 60 µg, and 180 µg.
Participants will receive three intramuscular injections at Weeks 0, 4, and 38, with follow-up visits through Week 58. The primary objective is to evaluate safety and tolerability. Secondary objectives include evaluation of anti-tau antibody responses and T-cell responses. Exploratory assessments include plasma Alzheimer's disease biomarkers, tau PET imaging, immune-response characteristics, and cognitive measures.
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease
- Being tested
- AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo
- Keywords
- Tau protein, Immunotherapy, Vaccine, Preclinical Alzheimer's Disease, Alzheimer's Disease, secondary prevention, Neurodegeneration, Preventive Alzheimer's
- Medical subject headings
- Alzheimer Disease, Frontotemporal Dementia, Nerve Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AV-1980R 20 µgBiological
AV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 20 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38.
AV-1980R 60 µgBiological
AV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 60 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38.
AV-1980R 180 µgBiological
AV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 180 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38.
PlaceboOther
The placebo consists of 10 mM phosphate buffer without active AV-1980R, formulated with Advax-CpG55.2, consisting of Advax and CpG55.2. It is administered by intramuscular injection at Weeks 0, 4, and 38.
| Study group | Role | What they receive |
|---|---|---|
| AV-1980R 20 µg Arm | Experimental | Participants receive 20 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38. Receives: Biological: AV-1980R 20 µg |
| AV-1980R 60 µg Arm | Experimental | Participants receive 60 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38. Receives: Biological: AV-1980R 60 µg |
| AV-1980R 180 µg Arm | Experimental | Participants receive 180 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38. Receives: Biological: AV-1980R 180 µg |
| Placebo Arm | Placebo comparator | Participants receive 10 mM phosphate buffer without active AV-1980R, formulated with Advax-CpG55.2, by intramuscular injection at Weeks 0, 4, and 38. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events
Number of participants who experience one or more treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs), summarized by severity and relationship to study intervention.
Measured: Baseline through Week 58
Secondary outcomes (10)
Number of Participants with Clinically Significant Changes in Vital Signs
Number of participants with clinically significant abnormalities or changes in blood pressure, heart rate, respiratory rate, or body temperature.
Measured: Baseline through Week 58
Number of Participants with Clinically Significant Changes in ECG Results
Number of participants with new or worsening clinically significant ECG abnormalities.
Measured: Baseline through Week 58
Number of Participants with Clinically Significant Changes in Laboratory Tests
Number of participants with new or worsening abnormalities in hematology, serum chemistry, coagulation, or urinalysis results.
Measured: Baseline through Week 58
Number of Participants with Clinically Significant Changes in Physical Examinations
Number of participants with new or worsening abnormal findings on physical examination.
Measured: Screening through Week 58
Number of Participants with Clinically Significant Changes in Neurological Examinations
Number of participants with new or worsening abnormal neurological findings.
Measured: Screening through Week 58
Number of Participants with New MRI Abnormalities, Including ARIA-E and ARIA-H
Number of participants with new MRI findings of vasogenic edema or sulcal effusion (ARIA-E), cerebral microhemorrhage, macrohemorrhage, or superficial siderosis (ARIA-H), or new ischemic findings.
Measured: Screening and Weeks 6, 40, and 58
Change from Baseline in Columbia-Suicide Severity Rating Scale Assessment
Change from baseline in suicidal ideation and behavior assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS).
Measured: Baseline and Weeks 38, 40, 50, and 58
Change from Baseline in Serum Anti-Tau Antibody Titers
Serum anti-tau antibody titers measured using a validated enzyme-linked immunosorbent assay.
Measured: Baseline through Week 58
Change from Baseline in MultiTEP-Specific T-Helper Cell Responses
MultiTEP-specific interferon-gamma-producing T-helper cells detected in peripheral blood mononuclear cells using an ELISPOT assay after stimulation with MultiTEP T-helper peptides.
Measured: Baseline through Week 58
Change from Baseline in Tau-Specific Autoreactive T-Helper Cell Responses
Tau-specific interferon-gamma-producing T-helper cells detected in peripheral blood mononuclear cells using an ELISPOT assay after stimulation with the Tau2-18 peptide.
Measured: Baseline through Week 58
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2025
- Study start23 Jun 2026
- Primary completion15 Jun 2029 (estimated)
- Study completion15 Oct 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized in a 3:1 ratio to receive AV-1980R or placebo across three ascending dose cohorts. Each participant gets one assigned intervention in parallel with others.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institute for Molecular Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Sponsor
- Investigators
- Michael Agadjanyan, PhD, Principal investigator, Institute MMRoman Kniazev, Study director, Institute MM
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07158905
- Sponsor's protocol ID
- IMM-AV1980R-102
- Other IDs
- 1R01AG092949-01
- Acronym
- TAURUS-1980
- Status last verified
- Jul 2026
- First submitted
- 27 Aug 2025
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of AV-1980R in Participants With Preclinical Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT07158905
- Acronym / sponsor ID
- TAURUS-1980 / IMM-AV1980R-102
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease
- Keywords
- Tau protein, Immunotherapy, Vaccine, Preclinical Alzheimer's Disease, Alzheimer's Disease, secondary prevention, Neurodegeneration, Preventive Alzheimer's
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- Institute for Molecular MedicineUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- 23 Jun 2026 (actual)
- Primary completion
- 15 Jun 2029 (estimated)
- Study completion
- 15 Oct 2029 (estimated)
- First posted
- 8 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65 to 80 years with biomarker evidence of preclinical Alzheimer's disease will be enrolled into three ascending-dose cohorts.
Detailed description
This study will evaluate AV-1980R, a MultiTEP-based active immunotherapy formulated with Advax-CpG55.2 adjuvant, in participants with preclinical Alzheimer's disease. Up to 48 participants aged 65 to 80 years will be randomized in a 3:1 ratio to receive AV-1980R or placebo in three ascending-dose cohorts of 20 µg, 60 µg, and 180 µg.
Participants will receive three intramuscular injections at Weeks 0, 4, and 38, with follow-up visits through Week 58. The primary objective is to evaluate safety and tolerability. Secondary objectives include evaluation of anti-tau antibody responses and T-cell responses. Exploratory assessments include plasma Alzheimer's disease biomarkers, tau PET imaging, immune-response characteristics, and cognitive measures.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- Participants are randomized in a 3:1 ratio to receive AV-1980R or placebo across three ascending dose cohorts. Each participant gets one assigned intervention in parallel with others.
| Arm | Type | Receives |
|---|---|---|
| AV-1980R 20 µg Arm | Experimental | Biological: AV-1980R 20 µgParticipants receive 20 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38. |
| AV-1980R 60 µg Arm | Experimental | Biological: AV-1980R 60 µgParticipants receive 60 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38. |
| AV-1980R 180 µg Arm | Experimental | Biological: AV-1980R 180 µgParticipants receive 180 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38. |
| Placebo Arm | Placebo comparator | Other: PlaceboParticipants receive 10 mM phosphate buffer without active AV-1980R, formulated with Advax-CpG55.2, by intramuscular injection at Weeks 0, 4, and 38. |
Who may qualify
- Ages
- 65 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (7 listed)
- Male or postmenopausal or surgically sterile female, 65 to 80 years of age, inclusive.
- Cognitively unimpaired participant with preclinical Alzheimer's disease who meets all of the following:
- Clinical Dementia Rating global score of 0 at Screening. Mini-Mental State Examination score ≥26, with education adjustment at Screening.
- Plasma p-tau217/Aβ42 ratio ≥0.00738 measured using Lumipulse (Fujirebio). A prior positive result obtained within 12 months before Screening may be accepted but must be confirmed by the central laboratory.
- Sight and hearing, including use of a hearing aid, sufficient to comply with study procedures.
Key exclusion criteria (14 listed)
- More than one noncortical lacunar infarct greater than 1.5 cm. Any territorial infarct greater than 1.5 cm. Combined microbleeds and areas of leptomeningeal hemosiderosis greater than 5, or disseminated leptomeningeal hemosiderosis.
- Any other significant cerebral abnormality, including ARIA-E. Contraindication to MRI, including non-MRI-safe implanted metallic devices or clinically significant claustrophobia.
- Serious illness requiring systemic treatment or hospitalization within 4 weeks before study entry.
- Clinically relevant cardiovascular, respiratory, gastrointestinal, endocrine, immunologic, hematologic, systemic disease, or major surgery that could interfere with participation or follow-up.
- Insulin-dependent diabetes. Clinically relevant cardiac arrhythmia, palpitation, conduction abnormality, prolonged QT interval, or bundle branch block.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AV-1980R 20 µgAV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 20 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38. | Biological | AV-1980R 20 µg Arm |
| AV-1980R 60 µgAV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 60 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38. | Biological | AV-1980R 60 µg Arm |
| AV-1980R 180 µgAV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 180 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38. | Biological | AV-1980R 180 µg Arm |
| PlaceboThe placebo consists of 10 mM phosphate buffer without active AV-1980R, formulated with Advax-CpG55.2, consisting of Advax and CpG55.2. It is administered by intramuscular injection at Weeks 0, 4, and 38. | Other | Placebo Arm |
Primary outcome
Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events
Time frame: Baseline through Week 58
Number of participants who experience one or more treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs), summarized by severity and relationship to study intervention.
10 secondary outcomes
Number of Participants with Clinically Significant Changes in Vital Signs
Time frame: Baseline through Week 58
Number of Participants with Clinically Significant Changes in ECG Results
Time frame: Baseline through Week 58
Number of Participants with Clinically Significant Changes in Laboratory Tests
Time frame: Baseline through Week 58
Number of Participants with Clinically Significant Changes in Physical Examinations
Time frame: Screening through Week 58
Number of Participants with Clinically Significant Changes in Neurological Examinations
Time frame: Screening through Week 58
Number of Participants with New MRI Abnormalities, Including ARIA-E and ARIA-H
Time frame: Screening and Weeks 6, 40, and 58
Change from Baseline in Columbia-Suicide Severity Rating Scale Assessment
Time frame: Baseline and Weeks 38, 40, 50, and 58
Change from Baseline in Serum Anti-Tau Antibody Titers
Time frame: Baseline through Week 58
Change from Baseline in MultiTEP-Specific T-Helper Cell Responses
Time frame: Baseline through Week 58
Change from Baseline in Tau-Specific Autoreactive T-Helper Cell Responses
Time frame: Baseline through Week 58
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Michael Agadjanyan, PhD principal investigator
Institute MM
Roman Kniazev study director
Institute MM
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AV-1980R 20 µg, AV-1980R 60 µg and AV-1980R 180 µg in people with Alzheimer Disease and Preclinical Alzheimer's Disease, run by Institute for Molecular Medicine at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Roman Kniazev (7145963981, rkniazev@immed.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events (time frame: Baseline through Week 58). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.